Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Sickle cell disease: an invisible illness with very real consequences
Often invisible from the outside, sickle cell disease remains one of the most common genetic disorders in France, affecting around 30.000 people. Behind this apparent invisibility lies a chronic condition that can deeply impact daily life.
This disease is caused by a genetic abnormality of hemoglobin, leading to the deformation of some red blood cells. Less flexible, these cells struggle to circulate through small blood vessels, causing pain crises, chronic anemia, and sometimes severe organ complications.
Treatment options are diverse: symptomatic care, prevention of complications, transfusions, and today, the development of gene therapies offering real hope for curative treatment.
Among the most effective approaches, red blood exchange by apheresis makes it possible to remove altered red blood cells and replace them with healthy donor red blood cells. This technique reduces blood viscosity, limits iron overload, and helps space out treatment sessions.
Beyond every protocol, there is one simple goal: helping patients live more freely.”
Other posts featuring Maxime Dely on Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow